Prescriber Criteria Form

Balversa 2025 PA Fax 2966-A v2 010125.docx
Balversa (erdafitinib)
Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.
Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673.** Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Balversa (erdafitinib).

Drug Name:
Balversa (erdafitinib)

Patient Name:		
Patient ID:		
Patient DOB:	**Patient Phone:**	
Prescriber Name:		
Prescriber Address:		
City:	**State:**	**Zip:**
Prescriber Phone:	**Prescriber Fax:**	
Diagnosis:	**ICD Code(s):**	

Please circle the appropriate answer for each question.			
1	Does the patient have a diagnosis of locally advanced, recurrent, or metastatic urothelial carcinoma? [If yes, then skip to question 3.]	Yes ◯	No ◯
2	Does the patient have a diagnosis of Stage II-IV, recurrent, or persistent urothelial carcinoma of the bladder? [If no, then no further questions.]	Yes ◯	No ◯
3	Does the disease have a susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alteration? [If no, then no further questions.]	Yes ◯	No ◯
4	Is the requested drug being used as subsequent therapy?	Yes ◯	No ◯

Comments:	_____

By signing this form, I attest that the information provided is accurate and true as of this date and that the documentation supporting this information is available for review if requested by the health plan.

Prescriber (or Authorized) Signature: _____ Date:_____